UK +44 (0)1865 849841
Malaysia +60 3 2117 5193

Tag: nafld

What does international collaboration mean for you?

The present COVID-19 crisis has demonstrated the vital need for knowledge sharing across the global science community. We asked three of our speakers what international collaboration means for them as leaders in their fields.

Read More

An Overview of Available Preclinical Models for Non-alcoholic Fatty Liver Disease

NASH is thought to affect 25% of the global population and is a primary risk factor for Hepatocellular carcinoma (HCC)  the second most common cause of cancer deaths worldwide. Understanding the aetiology of NAFLD progression, developing non-invasive diagnostic tests and developing treatments are urgent priorities.

Read More

Understanding the gut-liver axis: implications for NAFLD prevention and treatment

You may have heard; humans are superorganisms. The human large intestine harbors tens of trillions of microbes, which equates to roughly 2 kg of cells. For reference, that’s how much your brain weighs! Within the gut microbiome, it is estimated that there are over 1,000 different species of bacteria.

Read More

Novel biomarkers and the development of a point-of-care test for fatty liver disease

Ahead of The 3rd Global NASH Congress, Dr Bevin Gangadharan explains how he helped to discover novel NAFLD biomarkers and their role in the development of a point-of-care test for NAFLD.

Read More

Screening for NAFLD in primary care: a preventative wonder or are we barking up the wrong tree?

The burden of chronic liver disease has a substantial health and economic burden within the UK. Chronic liver disease is the fifth most common cause of death in the UK and of those five, it is the only one with numbers that are rising. With this in mind, it would make sense that earlier detection of liver disease in primary care is key to improving outcomes and reducing costs.

Read More

Understanding the Role of the Gut Microbiome in NAFLD

NAFLD is the primary contributor to chronic liver disease worldwide with incident rates of 20-30% in western countries and 5-18% in Asia. The discovery of early stage biomarkers for patients with the reversible form of the disease is therefore a research priority. Recent work has shown perturbation of the microbiome and specific microbiome-associated metabolites contribute to the phenotype of NAFLD.

Read More

The EMA reflection paper on chronic liver disease and its implications for drug development in NASH

The European Medicines Agency published a “Reflection paper on chronic liver diseases (PBC, PSC, and NASH)” in Autumn 2018. Elmer Schabel gives a detailed display of the contents of this first regulatory guidance with regard to NASH, as well as a preliminary evaluation of the initial feedback and input received by stakeholders.

Read More

Inhibiting NOX enzymes to treat multiple diseases with high medical need

NOX enzymes are a family of enzymes which amplify multiple signalling pathways associated with liver disease. At the Global NASH Congress, Alexandre Grassin shared a presentation about Genkyotex’s novel molecule GTK831, a NOX1/4 inhibitor, and the interim results from its phase two trial.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Life Sciences Twitter Feed

Archive